Enspryng
Enspryng (satralizumab) is a monoclonal antibody medication used to treat neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune condition that primarily affects the optic nerves and spinal cord. It is specifically indicated for adults who test positive for anti-aquaporin-4 (AQP4) antibodies, a marker found in a majority of NMOSD patients.
Enspryng is a targeted immunotherapy for adults with AQP4 antibody-positive NMOSD, designed to reduce autoimmune attacks on the central nervous system.
Key facts at a glance
- RxNorm
- 2391556
- Generic
- Enspryng
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Enspryng is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 (AQP4) antibody positive. NMOSD is a chronic autoimmune disorder that causes inflammation and damage to the optic nerves and spinal cord, potentially leading to vision loss, paralysis, and sensory disturbances.
Enspryng is a monoclonal antibody that targets and blocks the interleukin-6 (IL-6) receptor. IL-6 is a cytokine that plays a key role in driving the inflammatory immune response that damages nerve cells in NMOSD. By inhibiting IL-6 signaling, the medication helps reduce the autoimmune attack on the central nervous system.
Enspryng is administered as a subcutaneous injection, typically given every four weeks after initial loading doses. Common side effects may include headache, joint pain, and upper respiratory infections. Patients should be monitored for signs of infection during treatment, and it may increase the risk of serious infections. The medication should not be used in patients with active infections. Regular laboratory monitoring may be required during treatment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy